Teva Pharmaceutical Industries Limited (BVMF:T1EV34)
Brazil · Delayed Price · Currency is BRL | Market Cap | 208.03B +88.4% |
| Revenue (ttm) | 90.50B +4.4% |
| Net Income | 8.16B |
| EPS | 6.99 |
| Shares Out | n/a |
| PE Ratio | 25.48 |
| Forward PE | 15.58 |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 2 |
| Open | 81.96 |
| Previous Close | 86.40 |
| Day's Range | 81.96 - 81.96 |
| 52-Week Range | 42.67 - 97.29 |
| Beta | 0.86 |
| Analysts | n/a |
| Price Target | n/a |
| Earnings Date | Jul 29, 2026 |
About BVMF:T1EV34
Teva Pharmaceutical Industries Limited develops, manufactures, markets, and distributes generic and other medicines, and biopharmaceutical products in the United States, Europe, Israel, and internationally. It offers generic medicines in various dosage forms, such as tablets, capsules, injectables, inhalants, liquids, transdermal patches, ointments, and creams; sterile products, hormones, high-potency drugs, and cytotoxic substances in parenteral and solid dosage forms; and generic products with medical devices and combination products. The com... [Read more]
News
Teva put volume heavy and directionally bearish
Bearish flow noted in Teva (TEVA) with 4,549 puts trading, or 3x expected. Most active are 6/12 weekly 33.5 puts and Sep-26 40 calls, with total volume in those strikes…
Teva presents positive long-term study data for Austedo
Teva (TEVA) announced new data highlighting symptom improvement from treatment with Austedo and Austedo XR in patients with tardive dyskinesia. Findings from the real-world IMPACT-TD study evaluated p...
Teva's Data on AUSTEDO® (deutetrabenazine) tablets and AUSTEDO XR® (deutetrabenazine) extended-release tablets Highlight Long-Term Advances in Tardive Dyskinesia Treatment and Care
PARSIPPANY, N.J. and TEL AVIV, Israel, June 08, 2026 (GLOBE NEWSWIRE) -- Teva Pharmaceuticals, a U.S. affiliate of Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA), today announced new data t...
Teva Pharmaceutical Industries Transcript: Goldman Sachs 47th Annual Global Healthcare Conference 2026
Management outlined a disciplined growth strategy centered on innovation, generics expansion, and capital allocation, with major product launches and pipeline readouts expected through 2028. The company’s transformation into a biopharma leader is reinforced by robust execution, undervalued assets, and a strong outlook for long-term value creation.
Teva announces new data on AUSTEDO tablets, AUSTEDO XR tablets
Teva (TEVA) Pharmaceuticals announced new data from the first and only real-world, decentralized study evaluating the patient- and caregiver-reported quality of life impacts of Huntington’s disease ch...
Teva Presents New Data on AUSTEDO® (deutetrabenazine) tablets and AUSTEDO XR® (deutetrabenazine) extended-release tablets that Show Patient- and Caregiver-Reported Improvements in Huntington's Disease Chorea
PARSIPPANY, N.J. and TEL AVIV, Israel, June 05, 2026 (GLOBE NEWSWIRE) -- Teva Pharmaceuticals, a U.S. affiliate of Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA), today announced new data f...
Teva launches Ahzantive in Europe
Teva (TEVA) announced the launch of Ahzantive, a biosimilar to Eylea, in Europe. The launch of Ahzantive pre-filled syringes began in May across several European markets, including France, Germany, Sp...
Teva to Present at the Goldman Sachs Global Healthcare Conference
PARSIPPANY, N.J., and TEL AVIV, Israel, June 01, 2026 (GLOBE NEWSWIRE) -- Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) today announced that Richard Francis, Teva's President and CEO, will...
Teva Pharmaceutical Industries Just Pulled Off One of Pharma's Most Impressive Comebacks
Thanks to its pivot from generic to branded drug products, Teva Pharmaceutical Industries has experienced a dramatic price rebound. Even after surging 90% higher over the past year, Teva's comeback ma...
Teva commits to Veeva Vault CRM
Veeva Systems (VEEV) announced that Teva Pharmaceuticals (TEVA) has committed to Veeva Vault CRM globally. “We are excited to expand our strategic partnership with Veeva by moving to Vault CRM,”…
Teva announces EMA acceptance of MAA for olanzapine long-acting injectable
Teva (TEVA) Pharmaceuticals International announced that the European Medicines Agency has accepted the Marketing Authorization Application for olanzapine long-acting injectable for the treatment of s...
The European Medicines Agency Accepts Teva's Marketing Authorization Application for Olanzapine Long-Acting Injectable (TEV-‘749) for the Treatment of Schizophrenia in Adults
TEL AVIV, Israel and PARIS, May 21, 2026 (GLOBE NEWSWIRE) -- Teva Pharmaceuticals International GmbH, a subsidiary of Teva Pharmaceutical Industries Ltd. (NYSE: and TASE: TEVA) and Medincell (Euronext...
Fitch Upgrades Teva to Investment Grade Amid Pivot to Growth Execution
TEL AVIV, Israel, May 18, 2026 (GLOBE NEWSWIRE) -- Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) today announced that Fitch Ratings Agency (“Fitch”) has raised the Company's corporate cred...
Teva Study Finds Only 23% of Younger Adults with Mood Disorders and Tardive Dyskinesia (TD) Symptoms Are Formally Diagnosed with TD Despite Widespread Impact
PARSIPPANY, N.J. and TEL AVIV, Israel, May 18, 2026 (GLOBE NEWSWIRE) -- Teva Pharmaceuticals, a U.S. affiliate of Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA), today announced new data fr...
Teva Stock Is at Its Highest Level in Nearly a Decade. Here's Why It Could Soar Even More.
Teva is pivoting from generic-drug maker to major pharmaceutical company. Even after more than doubling in price over the past year, shares have more room to run, thanks to the company's robust pipeli...
Teva put volume heavy and directionally bearish
Bearish flow noted in Teva (TEVA) with 9,316 puts trading, or 8x expected. Most active are Jun-26 30 puts and Jun-26 37 calls, with total volume in those strikes near…
Teva Pharmaceutical Industries Transcript: Bank of America Global Healthcare Conference 2026
Accelerated development of five late-stage programs is enabled by strategic funding deals, aiming for annual launches through 2027. Key assets include anti-IL-15 for vitiligo, TL1A for IBD, and an oral alpha-synuclein agent, with robust device and generics strategies supporting growth.
Teva price target raised to $40 from $38 at Barclays
Barclays raised the firm’s price target on Teva (TEVA) to $40 from $38 and keeps an Overweight rating on the shares.
Teva to Present at the BofA Securities Health Care Conference
PARSIPPANY, N.J., and TEL AVIV, Israel, May 04, 2026 (GLOBE NEWSWIRE) -- Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) today announced that Eric Hughes, Teva's EVP of Global R&D & Chief Me...
Teva price target raised to $50 from $45 at Goldman Sachs
Goldman Sachs raised the firm’s price target on Teva (TEVA) to $50 from $45 and keeps a Buy rating on the shares. Teva delivered encouraging results, with strong outperformance in…
Teva price target raised to $40 from $35 at JPMorgan
JPMorgan raised the firm’s price target on Teva (TEVA) to $40 from $35 and keeps an Overweight rating on the shares.
Teva price target raised to $42 from $41 at Piper Sandler
Piper Sandler raised the firm’s price target on Teva (TEVA) to $42 from $41 and keeps an Overweight rating on the shares following quarterly results. The firm notes Teva continues…
Teva's 2025 Healthy Future Report Highlights Environmental and Access to Medicines Progress, Including Meeting All Sustainability-Linked Bond Targets
TEL AVIV, Israel, April 30, 2026 (GLOBE NEWSWIRE) -- Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) today published its 2025 Healthy Future Report, outlining performance against its sustain...
Teva price target raised to $42 from $36 at UBS
UBS raised the firm’s price target on Teva (TEVA) to $42 from $36 and keeps a Buy rating on the shares. Teva reported Q1 results that reinforce improving confidence in…
Teva price target raised to $45 from $42 at Truist
Truist raised the firm’s price target on Teva (TEVA) to $45 from $42 and keeps a Buy rating on the shares after announcing “strong” Q1 results, and the acquisition of…